Sector
PharmaceuticalsOpen
₹424.9Prev. Close
₹421.6Turnover(Lac.)
₹113.71Day's High
₹426Day's Low
₹412.952 Week's High
₹63052 Week's Low
₹375.05Book Value
₹194.37Face Value
₹10Mkt Cap (₹ Cr.)
562.65P/E
59.62EPS
6.97Divi. Yield
0.23Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 12.71 | 13.78 | 12.22 | 12.22 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 196.49 | 180.02 | 135.82 | 122.14 |
Net Worth | 209.2 | 193.8 | 148.04 | 134.36 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Revenue | 110.14 | 117.34 | 111.5 | 82.45 |
yoy growth (%) | -6.13 | 5.23 | 35.23 | 22.56 |
Raw materials | -66.87 | -72.95 | -67.65 | -49.2 |
As % of sales | 60.71 | 62.17 | 60.67 | 59.67 |
Employee costs | -8.79 | -9.29 | -9.05 | -6.65 |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Profit before tax | 16.75 | 16.6 | 13.9 | 6.35 |
Depreciation | -2.51 | -2.49 | -2.05 | -1.92 |
Tax paid | -4.26 | -4.34 | -3.78 | -1.19 |
Working capital | -1.38 | -8.09 | 38.28 | 6.51 |
Other operating items |
Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | -6.13 | 5.23 | 35.23 | 22.56 |
Op profit growth | 10.23 | 7.79 | 49.71 | 119.69 |
EBIT growth | 3.74 | 5.29 | 73.66 | 146.26 |
Net profit growth | 1.85 | 21.22 | 95.97 | 973.02 |
Particulars (Rupees in Crores.) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|---|
Gross Sales | 162.55 | 179.31 | 140.87 | 115.45 | 112.72 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 162.55 | 179.31 | 140.87 | 115.45 | 112.72 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 6.24 | 2.33 | 2.46 | 1.72 | 0.75 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,669.8 | 93.52 | 4,00,520.99 | 2,000.46 | 0.96 | 7,107.14 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,616 | 79.48 | 1,75,574.28 | 667 | 0.45 | 2,536 | 561.08 |
Cipla Ltd CIPLA | 1,513.8 | 25.39 | 1,22,186 | 1,485.4 | 1.06 | 4,254.47 | 397.41 |
Dr Reddys Laboratories Ltd DRREDDY | 1,321.5 | 20.61 | 1,10,263.53 | 1,200.7 | 0.61 | 5,546.3 | 345.76 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,222.5 | 57.29 | 1,09,167.44 | 474 | 0.99 | 2,385 | 224.33 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Non Executive Director
Sanjay Bansal
Chairman (Non-Executive)
Rahul Bishnoi
Non Executive Director
Ashwani Kumar Sharma
Independent Director
Harish Pande
Non Executive Director
S K Singh
Independent Director
Arun Kumar
Company Sec. & Compli. Officer
Parul Choudhary
Independent Director
Sumita Dwivedi
Non Executive Director
Vimal Kumar Shrawat.
Independent Director
Sangeeta Bishnoi
Independent Director
Ravi Kumar Bansal
1506 Chiranjiv Tower 43,
Nehru Place,
New Delhi - 110019
Tel: 91-11-47589500
Website: http://www.medicamen.com
Email: [email protected]
Narang Tower,
44 Community Centre, Naraina Ind Area,
New Delhi-110028
Tel: 91-11-41410592-94
Website: www.linkintime.co.in
Email: [email protected]
Summary
A diversified enterprise, Medicamen Biotech Limited (MBL) is a research-led pharmaceutical company involved in developing, manufacturing and marketing of finished dosage formulations for domestic as w...
Read More
Reports by Medicamen Biotech Ltd
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.